Thyroid dysfunction is common in older adults and poses diagnostic and management challenges for clinicians. In this narrative review, we present published data focusing on special considerations in the diagnosis and management of hypothyroidism and hyperthyroidism in older adults.
Methods:
A comprehensive literature search of the PubMed and Ovid MEDLINE databases was conducted from January 2000 to December 2024 to identify pertinent articles in English for this narrative review.
Results:
Due to significant cardiovascular risk if untreated, both overt hypothyroidism and hyperthyroidism should be treated in older adults. Findings from observational studies do not support treating older adults with subclinical hypothyroidism with a thyrotropin (TSH) <7 mIU/L. However, observational data have demonstrated an increased risk of cardiovascular mortality and stroke in older adults with subclinical hypothyroidism with TSH 7.0–9.9 mIU/L and of coronary heart disease, cardiovascular mortality, and heart failure in those with TSH ≥10 mIU/L, suggesting levothyroxine treatment in these individuals should be considered. Data from clinical trials failed to show improvement with levothyroxine in hypothyroidism symptoms or fatigue in older adults with subclinical hypothyroidism compared with placebo. Over- and under-replacement with thyroid hormone is common and should be avoided, as population-based studies have shown associations with adverse cardiovascular and skeletal events. Subclinical hyperthyroidism with a TSH <0.1 mIU/L should be treated in older individuals as it has been associated with increased cardiovascular risk and bone density loss based on observational data. Randomized controlled trials have shown that long-term low-dose methimazole is a viable alternative to radioactive iodine in older adults with hyperthyroidism.
Conclusions:
A personalized approach should be undertaken in the diagnosis and management of thyroid dysfunction in older adults. Multiple factors should be considered, including physiological age-related changes in thyroid function, comorbidities, and polypharmacy. Care should be taken to maintain euthyroidism in order to avoid adverse events.
Get full access to this article
View all access options for this article.
References
1.
JohansenME, MarcinekJP, Doo Young YunJ. Thyroid hormone use in the United States, 1997–2016. J Am Board Fam Med, 2020; 33(2):284–288.
2.
LivadasS, BothouC, AndroulakisI, et al.Response to Michalaki et al. re: “Levothyroxine replacement therapy and overuse: A timely diagnostic approach. Thyroid, 2019; 29(8):1169.
3.
TaylorPN, IqbalA, MinassianC, et al.Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: Evidence from a large community-based study. JAMA Intern Med, 2014; 174(1):32–39.
4.
BritoJP, RossJS, El KawkgiOM, et al.Levothyroxine use in the United States, 2008-2018. JAMA Intern Med, 2021; 181(10):1402–1405.
5.
SilversteinWK, GradyD. Overuse of levothyroxine in patients with subclinical hypothyroidism: Time to “leve”-out-thyroxine. JAMA Intern Med, 2021; 181(10):1286–1287.
6.
MediciBB, NygaardB, la CourJL, et al.Changes in prescription routines for treating hypothyroidism between 2001 and 2015: An observational study of 929,684 primary care patients in Copenhagen. Thyroid, 2019; 29(7):910–919.
7.
la CourJL, MediciBR, GrandMK, et al.Risk of over- and under-treatment with levothyroxine in primary care in Copenhagen, Denmark. Eur J Endocrinol, 2021; 185(5):673–679.
8.
AyalaIN, Soto JacomeC, Toro-TobonD, et al.Appropriateness of levothyroxine prescription: A multicenter retrospective study. J Clin Endocrinol Metab, 2023.
9.
SurksMI, HollowellJG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab, 2007; 92(12):4575–4582.
10.
AtzmonG, BarzilaiN, HollowellJG, et al.Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab, 2009; 94(4):1251–1254.
11.
WaringAC, ArnoldAM, NewmanAB, et al.Longitudinal changes in thyroid function in the oldest old and survival: The cardiovascular health study all-stars study. J Clin Endocrinol Metab, 2012; 97(11):3944–3950.
12.
BremnerAP, FeddemaP, LeedmanPJ, et al.Age-related changes in thyroid function: A longitudinal study of a community-based cohort. J Clin Endocrinol Metab, 2012; 97(5):1554–1562.
13.
PapaleontiouM, HaymartMR. Approach to and treatment of thyroid disorders in the elderly. Med Clin North Am, 2012; 96(2):297–310.
14.
van den BeldAW, VisserTJ, FeeldersRA, et al.Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab, 2005; 90(12):6403–6409.
15.
CappolaAR, AuchusRJ, El-Hajj FuleihanG, et al.Hormones and aging: An endocrine society scientific statement. J Clin Endocrinol Metab, 2023; 108(8):1835–1874.
16.
ChakerL, CappolaAR, MooijaartSP, et al.Clinical aspects of thyroid function during ageing. Lancet Diabetes Endocrinol, 2018; 6(9):733–742.
MariottiS, BarbesinoG, CaturegliP, et al.Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab, 1993; 77(5):1130–1134.
19.
PeetersRP, DebaveyeY, FliersE, et al.Changes within the thyroid axis during critical illness. Crit Care Clin, 2006; 22(1):41–55, vi.
20.
CarleA, PedersenIB, KnudsenN, et al.Hypothyroid symptoms fail to predict thyroid insufficiency in old people: A population-based case-control study. Am J Med, 2016; 129(10):1082–1092.
21.
TrivalleC, DoucetJ, ChassagneP, et al.Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc, 1996; 44(1):50–53.
22.
DoucetJ, TrivalleC, ChassagneP, et al.Does age play a role in clinical presentation of hypothyroidism? J Am Geriatr Soc, 1994; 42(9):984–986.
23.
VadivelooT, DonnanPT, MurphyMJ, et al.Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: The Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab, 2013; 98(3):1147–1153.
24.
Rodriguez-GutierrezR, MarakaS, OspinaNS, et al.Levothyroxine overuse: Time for an about face? Lancet Diabetes Endocrinol, 2017; 5(4):246–248.
25.
JonklaasJ, BiancoAC, BauerAJ, et al.; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid, 2014; 24(12):1670–1751.
26.
By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2023; 71(7):2052–2081.
27.
PapaleontiouM, CappolaAR. Thyroid-stimulating hormone in the evaluation of subclinical hypothyroidism. JAMA, 2016; 316(15):1592–1593.
28.
ChakerL, BaumgartnerC, den ElzenWP, et al.; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of stroke events and fatal stroke: An individual participant data analysis. J Clin Endocrinol Metab, 2015; 100(6):2181–2191.
29.
RodondiN, den ElzenWP, BauerDC, et al.; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 2010; 304(12):1365–1374.
MooijaartSP, Du PuyRS, StottDJ, et al.Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. JAMA, 2019; 322(20):1977–1986.
32.
StottDJ, RodondiN, KearneyPM, et al.; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med, 2017; 376(26):2534–2544.
33.
VillarHC, SaconatoH, ValenteO, et al.Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev, 2007; 2007(3):CD003419.
34.
RazviS, WeaverJU, ButlerTJ, et al.Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med, 2012; 172(10):811–817.
35.
GencerB, ColletTH, VirginiV, et al.; Thyroid Studies Collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: An individual participant data analysis from 6 prospective cohorts. Circulation, 2012; 126(9):1040–1049.
36.
BiondiB, CappolaAR, CooperDS. Subclinical hypothyroidism: A review. JAMA, 2019; 322(2):153–160.
37.
SantiniF, PincheraA, MarsiliA, et al.Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab, 2005; 90(1):124–127.
38.
RosenbaumRL, BarzelUS. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med, 1982; 96(1):53–55.
39.
GaviganC, AbbeyEJ, McGreadyJ, et al.Levothyroxine dosing in older adults: Recommendations derived from the Baltimore Longitudinal Study of Aging. Endocr Pract, 2023; 29(8):612–617.
40.
RazviS, RyanV, IngoeL, et al.Age-related serum thyroid-stimulating hormone reference range in older patients treated with levothyroxine: A randomized controlled feasibility trial (SORTED 1). Eur Thyroid J, 2020; 9(1):40–48.
41.
PapaleontiouM, GayBL, EsfandiariNH, et al.The impact of age in the management of hypothyroidism: Results of a Nationwide Survey. Endocr Pract, 2016; 22(6):708–715.
42.
BurchHB. Drug effects on the thyroid. N Engl J Med, 2019; 381(8):749–761.
KundraP, BurmanKD. The effect of medications on thyroid function tests. Med Clin North Am, 2012; 96(2):283–295.
45.
LivecchiR, CoeAB, Reyes-GastelumD, et al.Concurrent use of thyroid hormone therapy and interfering medications in older US veterans. J Clin Endocrinol Metab, 2022; 107(7):e2738–e2742.
46.
SomwaruLL, ArnoldAM, JoshiN, et al.High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab, 2009; 94(4):1342–1345.
47.
MammenJS, McGreadyJ, OxmanR, et al.Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: Findings from the Baltimore longitudinal study of aging. Thyroid, 2015; 25(9):979–986.
48.
SawinCT, GellerA, WolfPA, et al.Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med, 1994; 331(19):1249–1252.
FlynnRW, BonellieSR, JungRT, et al.Serum thyroid-stimulating hormone concentration and morbidity cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab, 2010; 95(1):186–193.
51.
ThayakaranR, AdderleyNJ, SainsburyC, et al.Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: Longitudinal study. BMJ, 2019; 366:l4892.
52.
EvronJM, HummelSL, Reyes-GastelumD, et al.Association of thyroid hormone treatment intensity with cardiovascular mortality among US Veterans. JAMA Netw Open, 2022; 5(5):e2211863.
53.
Lillevang-JohansenM, AbrahamsenB, JorgensenHL, et al.Over- and under-treatment of hypothyroidism is associated with excess mortality: A register-based cohort study. Thyroid, 2018; 28(5):566–574.
54.
UzzanB, CamposJ, CucheratM, et al.Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab, 1996; 81(12):4278–4289.
55.
TurnerMR, CamachoX, FischerHD, et al.Levothyroxine dose and risk of fractures in older adults: Nested case-control study. BMJ, 2011; 342:d2238.
56.
MoonJH, JungKY, KimKM, et al.The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma. Bone, 2016; 83:104–110.
57.
PapaleontiouM, BanerjeeM, Reyes-GastelumD, et al.Risk of osteoporosis and fractures in patients with thyroid cancer: A case-control study in U.S. veterans. Oncologist, 2019; 24(9):1166–1173.
58.
WangLY, SmithAW, PalmerFL, et al.Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid, 2015; 25(3):300–307.
59.
MoonJH, KimKM, OhTJ, et al.The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2017; 102(1):78–85.
60.
SinhaSH, ZietlowK, PapaleontiouM. Thyroid function and cognitive decline: A narrative review. Endocr Pract, 2024; 30(11):1113–1118.
61.
WuY, PeiY, WangF, et al.Higher FT4 or TSH below the normal range are associated with increased risk of dementia: A meta-analysis of 11 studies. Sci Rep, 2016; 6:31975.
62.
AdamsR, OhES, YasarS, et al.Endogenous and exogenous thyrotoxicosis and risk of incident cognitive disorders in older adults. JAMA Intern Med, 2023; 183(12):1324–1331.
63.
BurgosN, TolozaFJK, Singh OspinaNM, et al.Clinical outcomes after discontinuation of thyroid hormone replacement: A systematic review and meta-analysis. Thyroid, 2021; 31(5):740–751.
64.
MorettiB, LivecchiR, TaylorSR, et al.Physician-reported barriers and facilitators to thyroid hormone deprescribing in older adults. J Am Geriatr Soc, 2025; 73(2):566–573.
65.
RavensbergAJ, PoortvlietRKE, Du PuyRS, et al.Effects of discontinuation of levothyroxine treatment in older adults: Protocol for a self-controlled trial. BMJ Open, 2023; 13(4):e070741.
66.
PapaleontiouM. (PI). Optimizing Care for Older Adults through Thyroid Hormone Deprescribing. National Institute on Aging; 2023.
67.
NordykeRA, GilbertFIJr, HaradaAS. Graves’ disease. Influence of age on clinical findings. Arch Intern Med, 1988; 148(3):626–631.
68.
BoelaertK, TorlinskaB, HolderRL, et al.Older subjects with hyperthyroidism present with a paucity of symptoms and signs: A large cross-sectional study. J Clin Endocrinol Metab, 2010; 95(6):2715–2726.
69.
DiezJJ. Hyperthyroidism in patients older than 55 years: An analysis of the etiology and management. Gerontology, 2003; 49(5):316–323.
70.
MorgantiS, CedaGP, SaccaniM, et al.Thyroid disease in the elderly: Sex-related differences in clinical expression. J Endocrinol Invest, 2005; 28(11 Suppl Proceedings):101–104.
71.
RosarioPW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: A prospective study. Clin Endocrinol (Oxf), 2010; 72(5):685–688.
72.
MitchellJE, HellkampAS, MarkDB, et al.Thyroid function in heart failure and impact on mortality. JACC Heart Fail, 2013; 1(1):48–55.
73.
RossDS, BurchHB, CooperDS, et al.2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016; 26(10):1343–1421.
74.
YangLB, JiangDQ, QiWB, et al.Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: An updated meta-analysis of cohort studies. Eur J Endocrinol, 2012; 167(1):75–84.
75.
KimHJ, McLeodDSA. Subclinical hyperthyroidism and cardiovascular disease. Thyroid, 2024; 34(11):1335–1345.
76.
ColletTH, GusseklooJ, BauerDC, et al.; Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med, 2012; 172(10):799–809.
77.
SelmerC, OlesenJB, HansenML, et al.Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: A large population study. J Clin Endocrinol Metab, 2014; 99(7):2372–2382.
78.
SegnaD, BauerDC, FellerM, et al.; Thyroid Studies Collaboration. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. J Intern Med, 2018; 283(1):56–72.
79.
GarinMC, ArnoldAM, LeeJS, et al.Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: The Cardiovascular Health Study. J Clin Endocrinol Metab, 2014; 99(8):2657–2664.
80.
SvareA, NilsenTI, AsvoldBO, et al.Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway. Eur J Endocrinol, 2013; 169(6):845–852.
81.
WaringAC, HarrisonS, FinkHA, et al.; Osteoporotic Fractures in Men (MrOS) Study. A prospective study of thyroid function, bone loss, and fractures in older men: The MrOS study. J Bone Miner Res, 2013; 28(3):472–479.
82.
FormigaF, FerrerA, PadrosG, et al.; Octabaix Study Group. Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: The OCTABAIX study. Eur J Endocrinol, 2014; 170(1):69–75.
83.
de JonghRT, LipsP, van SchoorNM, et al.Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol, 2011; 165(4):545–554.
84.
AubertCE, BauerDC, da CostaBR, et al.; Health ABC Study. The association between subclinical thyroid dysfunction and dementia: The Health, Aging and Body Composition (Health ABC) Study. Clin Endocrinol (Oxf), 2017; 87(5):617–626.
85.
AziziF, AbdiH, CheraghiL, et al.Treatment of subclinical hyperthyroidism in the elderly: Comparison of radioiodine and long-term methimazole treatment. Thyroid, 2021; 31(4):545–551.
86.
van SoestbergenMJ, van der VijverJC, GraaflandAD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: A comparison with Graves’ disease. J Endocrinol Invest, 1992; 15(11):797–800.
87.
SahliZT, AnsariG, GurakarM, et al.Thyroidectomy in older adults: An American College of Surgeons National Surgical Quality Improvement Program study of outcomes. J Surg Res, 2018; 229:20–27.
88.
BarbierMP, MingoteE, SforzaN, et al.Incidence and predictive factors of postoperative hypocalcaemia according to type of thyroid surgery in older adults. Endocrine, 2022; 75(1):276–283.
89.
GroganRH, MitmakerEJ, HwangJ, et al.A population-based prospective cohort study of complications after thyroidectomy in the elderly. J Clin Endocrinol Metab, 2012; 97(5):1645–1653.
90.
FinnertyBM, GrayKD, UllmannTM, et al.Frailty is more predictive than age for complications after thyroidectomy for multinodular goiter. World J Surg, 2020; 44(6):1876–1884.
